An overview of methods dedicated to protection of the digestive tract in patients treated with aspirin. Focus on clinical effectiveness and antiplatelet properties;Przegla̧d metod ochrony przewodu pokarmowego u pacjentów leczonych kwasem acetylosalicylowym. Ocena skuteczności terapii i wpływu na właściwości przeciwpłytkowe

Kardiologia Polska

Volumn 70, Issue 4, 2012, Pages 405-413

  Kasprzak, Michał ^a   Kozinśki, Marek ^a   Kubica, Aldona ^a   Navarese, Eliano Pio ^a   Grzesḱ, Grzegorz ^a   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PROTON PUMP INHIBITOR;

CLINICAL EFFECTIVENESS; DIGESTIVE SYSTEM; MITRAL VALVE REPLACEMENT; REVIEW; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ASPIRIN; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84860324550     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Bryniarski L, Pelc-Nowicka A, Zabojszcz M, Mirek-Bryniarska E. Dual antiplatelet therapy and antithrombotic treatment: recommendations and controversies. Cardiol J, 2009; 16: 179-189.
2. Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J, 2004; 25: 166-181. (Pubitemid 38112156)
3. Tompkins C, Henrikson CA. Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation. Cardiol J, 2011; 18: 103-109.
4. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937-944.
5. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009; 180: 713-718.
6. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860.
7. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med, 2008; 121: 43-49.
8. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil, 2007; 14 (suppl. 2): S1-S113. (Pubitemid 47339826)
9. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2009; 150: 405-410.
10. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med, 1989; 86: 449-458. (Pubitemid 19103913)
11. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ, 2000; 321: 1183-1187.
12. Smecuol E, Pinto Sanchez MI, Suarez A et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol, 2009; 7: 524-529.
13. Kushner FG, Hand M, Smith SC, Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2009; 54: 2205-2241.
14. Patrono C, Ciabattoni G, Patrignani P et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 1985; 72: 1177-1184. (Pubitemid 16126796)
15. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke, 2004; 35: 175-178. (Pubitemid 38057615)
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.
17. Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 2003; 108: 1682-1687. (Pubitemid 37243654)
18. Mehta SR, Bassand JP, Chrolavicius S et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med, 2010; 363: 930-942.
19. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk, 1996; 3: 209-212. (Pubitemid 26266495)
20. Swaim L, Hillman RS Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study. J Thromb Thrombolysis, 2009; 28: 94-100.
21. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002; 346: 2033-2038. (Pubitemid 34680594)
22. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005; 352: 238-244. (Pubitemid 40110812)
23. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med, 2001; 344: 967-973. (Pubitemid 32240315)
24. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev, 2002; 4: CD002296.
25. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ, 2004; 329: 948.
26. Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010; 138: 82-88.
27. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol, 2007; 102: 507-515. (Pubitemid 46328156)
28. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart, 2010; 96: 368-371.
29. Inarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol, 2000; 35: 242-246. (Pubitemid 30217174)
30. Adamopoulos AB, Sakizlis GN, Nasothimiou EG et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol, 2009; 54: 163-168.
31. Kasprzak M, Kozinski M, Bielis L et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J, 2009; 16: 535-544.
32. Lev EI, Ramabadran RS, Guthikonda S et al. Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol, 2007; 99: 124-128. (Pubitemid 44969352)
33. Gudjonsson H, Oddsson E,Thjodleifsson B. Does sucralfate prevent short-term NSAID induced damage to the gastroduodenal mucosa? Digestion, 1994; 55: 395-398.
34. Agrawal NM, Roth S, Graham DY et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med, 1991; 115: 195-200.
35. Squadrito F, Lualdi P, Biffignandi P. Antiplatelet effects of a new sucralfate-coated aspirin formulation. Curr Ther Res Clin E, 1998; 59: 812-817. (Pubitemid 28533008)
36. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med, 1996; 28: 204-210. (Pubitemid 26088113)
37. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med, 2002; 162: 169-175. (Pubitemid 34098186)
38. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID- -induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol, 1996; 91: 223-227. (Pubitemid 126734008)
39. Kodaira C, Furuta T, Sugimoto M et al. W1061 AGA Abstracts protective effect of nitrates on the risk of ulcer bleedings induced by aspirin in Japan. Gastroenterology, 2008; 134: A625.
40. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ, 2011; 183: 310-319.
41. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA, 2004; 292: 1955-1960. (Pubitemid 39411203)
42. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA, 2005; 294: 2989-2995. (Pubitemid 41817660)
43. Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med, 2010; 170: 784-790.
44. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ, 2008; 179: 319-326.
45. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA, 2006; 296: 2947-2953. (Pubitemid 46021498)
46. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol, 1991; 32: 77-83.
47. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther, 1999; 13: 1109-1114. (Pubitemid 29374114)
48. Nikolsky E, Mehran R, Stone GW, Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. Am J Cardiol, 2009; 104: 22C-29C.
49. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008; 118: 1894-1909.
50. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol, 2010; 56: 2051-2066.